Get the Stockscreener App
6.42
42.67%
1.92
4 D Molecular Therapeutics Inc stock is traded at $6.42, with a volume of 31.41M.
It is up +42.67% in the last 24 hours and up +54.70% over the past month.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
See More
Previous Close:
$4.50
Open:
$5.28
24h Volume:
31.41M
Relative Volume:
35.05
Market Cap:
$297.40M
Revenue:
$20.72M
Net Income/Loss:
$-100.84M
P/E Ratio:
-2.4135
EPS:
-2.66
Net Cash Flow:
$-78.56M
1W Performance:
+40.48%
1M Performance:
+54.70%
6M Performance:
+14.64%
1Y Performance:
-62.65%
1-Day Range:
$4.99
$6.69
1-Week Range:
$4.274
$6.69
52-Week Range:
$2.235
$17.41
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Name
4 D Molecular Therapeutics Inc
Sector
Industry
Phone
(510) 505-2680
Address
5858 HORTON STREET #455, EMERYVILLE
Compare FDMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
6.42 | 208.46M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Nov-21-24 | Initiated | Morgan Stanley | Underweight |
| Sep-23-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Apr-15-24 | Initiated | Barclays | Overweight |
| Feb-07-24 | Resumed | Goldman | Buy |
| Oct-26-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-18-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-18-22 | Initiated | H.C. Wainwright | Buy |
| Nov-15-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-12-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-22-22 | Initiated | Jefferies | Buy |
| Jan-04-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-21 | Initiated | BofA Securities | Buy |
| Jan-05-21 | Initiated | Evercore ISI | Outperform |
| Jan-05-21 | Initiated | Goldman | Neutral |
View All
4 D Molecular Therapeutics Inc Stock (FDMT) Latest News
Why 4D Molecular Therapeutics Inc. stock attracts strong analyst attentionFree Low Risk Swing Trade Opportunity List - Newser
4D Molecular Therapeutics Inc. stock prediction for this weekLow Drawdown Picks with Weekly Updates - Newser
4D Molecular Therapeutics Showcases Positive Trial Results, Charts New Growth Trajectory - timothysykes.com
4D Molecular (FDMT) Stock Climbs Following Promising Retina Therapy Data - Stocks Telegraph
4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study - 富途牛牛
How volatile is 4D Molecular Therapeutics Inc. stock compared to the marketEntry Signal Forecasts With Low Risk - jammulinksnews.com
4D Molecular Therapeutics: A Market Shift? - timothysykes.com
4D Molecular Therapeutics shares rise 30.44% premarket after presenting positive 60-week results for 4D-150. - AInvest
4D Molecular Therapeutics stock soars after positive DME trial results By Investing.com - Investing.com Canada
Will a bounce in 4D Molecular Therapeutics Inc. offer an exitPrice Action Trading with Volume Confirmation - Newser
4D Molecular Therapeutics Shares Surge 50.89% on Positive Clinical Trial Results - AInvest
4D Molecular Therapeutics (FDMT) Shares Soar 37.78% on Positive Clinical Trial Results - AInvest
4D Molecular Therapeutics shares rise 56% premarket after presenting positive 60-week results for 4D-150. - AInvest
Using fundamentals and technicals on 4D Molecular Therapeutics Inc.Capital Growth Summary Over Five Years - Newser
4D Molecular (FDMT) Shows Promising Results in Clinical Trial fo - GuruFocus
What is the risk reward ratio of investing in 4D Molecular Therapeutics Inc. stockTop Growth Alerts With Proven Results - jammulinksnews.com
4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update - GlobeNewswire
Breakthrough: 4D-150 DME Treatment Shows 78% Reduction in Injections, FDA and EMA Clear Path to Approval - Stock Titan
Is 4D Molecular Therapeutics Inc. Stock a Good Fit for Conservative InvestorsAI Screener for Daily Stock Forecast - Newser
How does 4D Molecular Therapeutics Inc. compare to its industry peersBeginner Investor Strategy With Proven Results - jammulinksnews.com
What makes 4D Molecular Therapeutics Inc. stock attractive to long term investorsOversold Reversal Picks with Buy Zone - Newser
Trend Reversal Possible in 4D Molecular Therapeutics Inc. Charts IndicateEarnings Play Trade Plan With Alerts Shared - beatles.ru
Advanced analytics toolkit walkthrough for 4D Molecular Therapeutics Inc.Real Time Trade Execution Alert Plan - Newser
Weiss Ratings Reiterates Sell (D-) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
Published on: 2025-07-29 16:44:26 - Newser
How 4D Molecular Therapeutics Inc. stock performs during market volatilityPortfolio Positioning Strategy With Timing - Newser
What makes 4D Molecular Therapeutics Inc. stock price move sharplyMinimal Risk Growth Investment Opportunity Analysis - Newser
4D Molecular Therapeutics Bets Big On Gene Therapy Breakthroughs - Finimize
Published on: 2025-07-29 09:03:48 - metal.it
Published on: 2025-07-29 02:38:48 - metal.it
Trapped Investors in 4D Molecular Therapeutics Inc. Await Breakout SignalTriple Digit Return Stock Predictions Released - metal.it
What catalysts could drive 4D Molecular Therapeutics Inc. stock higher in 2025Stay informed with expert market forecasts - jammulinksnews.com
Why is 4D Molecular Therapeutics Inc. stock attracting strong analyst attentionCapitalize on emerging industry trends - jammulinksnews.com
How does 4D Molecular Therapeutics Inc. generate profit in a changing economyUnlock powerful market trend analysis - jammulinksnews.com
Analyzing drawdowns of 4D Molecular Therapeutics Inc. with statistical toolsHigh Conviction Screener with Trend Matching - Newser
What makes 4D Molecular Therapeutics Inc. stock attractive to long term investors Free Opportunity Map for Daily Stock Trading - Newser
What is the dividend policy of 4D Molecular Therapeutics Inc. stockSuperior portfolio returns - jammulinksnews.com
Is 4D Molecular Therapeutics Inc. stock overvalued or undervaluedMarket Forecast Insights For 2025 - jammulinksnews.com
Is 4D Molecular Therapeutics Inc. a growth stock or a value stockFree Stock Movement Tracking - jammulinksnews.com
What is 4D Molecular Therapeutics Inc. company’s growth strategyInvest smarter with data-backed insights - jammulinksnews.com
What are the technical indicators suggesting about 4D Molecular Therapeutics Inc.Unlock expert insights for smarter investing - jammulinksnews.com
Sectors Driving Future Growth for 4D Molecular Therapeutics Inc. StockProven Trading Plan - Newser
Published on: 2025-07-27 17:37:47 - jammulinksnews.com
Published on: 2025-07-27 13:56:04 - jammulinksnews.com
What drives 4D Molecular Therapeutics Inc. stock priceRapidly expanding wealth - PrintWeekIndia
4D Molecular Therapeutics Inc. Stock Analysis and ForecastTremendous portfolio expansion - PrintWeekIndia
4D Molecular Therapeutics Announces Presentations at ASRS 2025 on Phase 2 Clinical Trials for 4D-150 in Diabetic Macular Edema and Neovascular Age-related Macular Degeneration - Nasdaq
4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists - GlobeNewswire
4 D Molecular Therapeutics Inc Stock (FDMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):